BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15378500)

  • 1. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma.
    Shah L; Walter KL; Borczuk AC; Kawut SM; Sonett JR; Gorenstein LA; Ginsburg ME; Steinglass KM; Powell CA
    Cancer; 2004 Oct; 101(7):1632-8. PubMed ID: 15378500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
    Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
    Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung.
    Pelosi G; Fraggetta F; Pasini F; Maisonneuve P; Sonzogni A; Iannucci A; Terzi A; Bresaola E; Valduga F; Lupo C; Viale G
    Am J Surg Pathol; 2001 Mar; 25(3):363-72. PubMed ID: 11224607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
    Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
    Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.
    Argon A; Nart D; Veral A
    Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor.
    Toyoshima E; Ohsaki Y; Nishigaki Y; Fujimoto Y; Kohgo Y; Kikuchi K
    Lung Cancer; 2001; 31(2-3):193-202. PubMed ID: 11165398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.
    Ohsaki Y; Tanno S; Fujita Y; Toyoshima E; Fujiuchi S; Nishigaki Y; Ishida S; Nagase A; Miyokawa N; Hirata S; Kikuchi K
    Oncol Rep; 2000; 7(3):603-7. PubMed ID: 10767376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study.
    Tan D; Li Q; Deeb G; Ramnath N; Slocum HK; Brooks J; Cheney R; Wiseman S; Anderson T; Loewen G
    Hum Pathol; 2003 Jun; 34(6):597-604. PubMed ID: 12827614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival.
    Selvaggi G; Scagliotti GV; Torri V; Novello S; Leonardo E; Cappia S; Mossetti C; Ardissone F; Lausi P; Borasio P
    Cancer; 2002 May; 94(10):2669-74. PubMed ID: 12173335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
    Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
    J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis.
    Yaman B; Nart D; Ekren PK; Çok G; Veral A
    Turk Patoloji Derg; 2015; 31(3):163-74. PubMed ID: 26456962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
    Volm M; Koomägi R
    Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival.
    Donnem T; Andersen S; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
    Cancer; 2010 Dec; 116(24):5676-85. PubMed ID: 20737536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of BCL-6 protein and CD138/syndecan-1 as B-cell markers in Hodgkin's disease.
    Carbone A; Gloghini A; Gaidano G
    Int J Biol Markers; 1999; 14(3):144-8. PubMed ID: 10569135
    [No Abstract]   [Full Text] [Related]  

  • 16. A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers.
    Lingfei K; Pingzhang Y; Zhengguo L; Jianhua G; Yaowu Z
    Cancer Lett; 1998 Aug; 130(1-2):93-101. PubMed ID: 9751261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
    Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
    J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.
    Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C
    Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck.
    Inki P; Joensuu H; Grénman R; Klemi P; Jalkanen M
    Br J Cancer; 1994 Aug; 70(2):319-23. PubMed ID: 8054282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
    Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
    Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.